Compare · ANPC vs CI
ANPC vs CI
Side-by-side comparison of AnPac Bio-Medical Science Co. Ltd. (ANPC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANPC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.25B, about 2073.0x ANPC ($37.7M).
- CI has hit the wire 4 times in the past 4 weeks while ANPC has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for ANPC).
- Company
- AnPac Bio-Medical Science Co. Ltd.
- The Cigna Group
- Price
- $4.53-7.74%
- $295.88+0.30%
- Market cap
- $37.7M
- $78.25B
- 1M return
- -
- +2.39%
- 1Y return
- -
- -4.59%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
AnPac Bio-Medical Science Co. Ltd.
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest ANPC
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 3 filed by new insider Liang Zhijun
- SEC Form 3 filed by new insider Zhao Zhigang
- SEC Form 3 filed by new insider Li Xiaoyu
- SEC Form 3 filed by new insider Pu Tianruo
- SEC Form 3 filed by new insider Tian Honggang
- New insider Xu Haohan claimed ownership of 69,774,679 units of Class A Ordinary Shares (SEC Form 3) (Amendment)
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group